Quick summary
Exenatide is a synthetic version of exendin-4 from Gila monster venom and was the first FDA-approved GLP-1 receptor agonist (2005). It is sold as twice-daily Byetta and once-weekly Bydureon and is indicated for type 2 diabetes glycemic control.
Overview
Exenatide is a synthetic version of exendin-4, a naturally occurring peptide found in the venom of the Gila monster lizard. The first GLP-1 receptor agonist approved by the FDA (2005), it shares approximately 50% amino acid homology with human GLP-1. Available as twice-daily Byetta and once-weekly extended-release Bydureon, it remains a foundational treatment for type 2 diabetes.
Mechanism of action
Exenatide binds and activates the glucagon-like peptide-1 receptor (GLP-1R), a G-protein coupled receptor expressed on pancreatic beta cells, gut, brain, heart, and kidneys. Activation triggers glucose-dependent insulin secretion via cAMP-PKA and Epac2 signaling, suppresses inappropriately elevated glucagon from pancreatic alpha cells, and slows gastric emptying—collectively blunting postprandial glucose excursions. Unlike native GLP-1 (half-life ~2 min), exenatide resists degradation by dipeptidyl peptidase-4 (DPP-4) due to an alanine-to-glycine substitution at position 2. Central GLP-1R activation in the hypothalamus and brainstem reduces appetite and increases satiety, contributing to the weight loss observed clinically.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| type 2 diabetes glycemic control (Byetta) | subcutaneous | 5–10 mcg | twice daily | Start at 5 mcg BID for 1 month, then increase to 10 mcg BID if tolerated. Inject 60 minutes before morning and evening meals. |
| type 2 diabetes glycemic control (Bydureon) | subcutaneous | 2–2 mg | once weekly | Fixed dose of 2 mg once weekly. No titration required. Rotate injection site. Extended-release microsphere formulation. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Pivotal AMIGO trials (2004–2005) demonstrated HbA1c reductions of 0.8–1.1% and weight loss of 2–3 kg vs. placebo over 30 weeks in type 2 diabetes. DURATION trials for Bydureon showed HbA1c reduction of ~1.3–1.6% with once-weekly dosing. Unlike some GLP-1 agents, cardiovascular outcome data (EXSCEL trial, 14,752 patients) showed noninferiority but not superiority for major adverse cardiovascular events vs. placebo.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Exenatide for synergistic effects.
Legal status
FDA-approved since April 2005 (Byetta) and January 2012 (Bydureon BCise). Schedule: unscheduled prescription drug. No generic available in the US as of 2026. Indicated for type 2 diabetes mellitus as adjunct to diet and exercise. Off-label use for obesity is common but less prevalent since newer agents (semaglutide, tirzepatide) entered market.
Sourcing & access
Prescription required
Exenatide is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the venom of the Gila monster lizard. It was the first GLP-1 receptor agonist approved by the FDA and is sold as Byetta and Bydureon.
Exenatide binds and activates the GLP-1 receptor on pancreatic beta cells, triggering glucose-dependent insulin secretion. It also suppresses inappropriately elevated glucagon and slows gastric emptying. An alanine-to-glycine substitution at position 2 makes it resistant to DPP-4 degradation.
Yes — exenatide was FDA-approved in April 2005 as Byetta and in January 2012 as Bydureon BCise. It is indicated for type 2 diabetes as an adjunct to diet and exercise.
Byetta is started at 5 mcg twice daily subcutaneously for 1 month, then increased to 10 mcg twice daily if tolerated, injected 60 minutes before the morning and evening meals. Bydureon is a fixed 2 mg once-weekly dose with no titration required.
The most common side effects are gastrointestinal: nausea (usually transient), vomiting, and diarrhea. Hypoglycemia can occur when combined with sulfonylureas, and rare reports include acute pancreatitis, renal impairment, and a GLP-1 class warning for medullary thyroid carcinoma risk from animal data.
Byetta has a half-life of approximately 2.4 hours, which is why it requires twice-daily dosing. Bydureon has an apparent half-life of about 2 weeks because of its extended-release microsphere formulation.
Exenatide is a short-acting exendin-4 analog with roughly 50% homology to native GLP-1, while semaglutide is a long-acting human GLP-1 analog. Semaglutide has largely superseded exenatide for weight loss due to superior efficacy and simpler dosing.
Research references
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesPubMed
- Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesPubMed
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (DURATION-1)PubMed
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL)PubMed